Literature DB >> 18418591

Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning.

Elisa Caballero-Calabuig1, Carmen Cano-Terol, Ramón Sopena-Monforte, Dolores Reyes-Ojeda, Pedro Abreu-Sánchez, José Ferrer-Rebolleda, Pablo Sopena-Novales, Carmen Plancha-Mansanet, Jesús Félix-Fontestad.   

Abstract

PURPOSE: Stimulated thyroglobulin (Tg) and (131)I total-body scan (TBS) have been the mainstays of differentiated thyroid carcinoma (DTC), but now diagnostic TBS has been eliminated from some follow-up protocols. Nevertheless, Tg can be negative in the presence of thyroid tissue, and moderately elevated Tg poses management problems. The purpose of this study was to check how many patients have Tg negative but visible thyroid tissue and if diagnostic TBS could be clinically useful.
MATERIAL AND METHODS: Retrospective review of 317 exams (stimulated Tg and TBS) of 128 patients with DTC. Patients with high-grade criteria and/or positive autoantibodies are excluded. Tg is considered positive if higher than the sensitivity level of the technique. TBS is positive if thyroid remnant, lymphatic node or metastases are detected. Results are classified in Tg and TBS concordant or discordant.
RESULTS: Discordant (131)I TBS and Tg were found in 74/317 studies (23.3%), 48 (65%) being TBS positive and Tg negative. None of 128 patients had a first post-surgery negative scan, but 13 (10%) were Tg negative, even two patients with lymph node uptake. One year after radioiodine treatment, 26 out of 115 patients (initially Tg and TBS concordant positive) showed Tg negative and TBS still positive due to cervical remnants (20 patients), lymph node uptake (one) and metastasis (five); 20 patients remained Tg and TBS positive, but 14 of them only showed thyroid remnants.
CONCLUSIONS: We propose to perform periodic diagnostic TBS to improve Tg specificity, at least while neck thyroid activity is detected, even if Tg is negative.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18418591     DOI: 10.1007/s00259-008-0789-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

2.  Procedure guideline for therapy of thyroid disease with (131)iodine.

Authors:  Donald A Meier; David R Brill; David V Becker; Susan E M Clarke; Edward B Silberstein; Henry D Royal; Helena R Balon
Journal:  J Nucl Med       Date:  2002-06       Impact factor: 10.057

3.  [Controversies in the follow-up and management of well-differentiated thyroid cancer. New answers to old questions].

Authors:  M D Abós Olivares; C Pesquera González
Journal:  Rev Esp Med Nucl       Date:  2005 May-Jun

4.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.

Authors:  C Bal; A K Padhy; S Jana; G S Pant; A K Basu
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

Review 5.  The use of radioactive iodine in patients with papillary and follicular thyroid cancer.

Authors:  L Wartofsky; S I Sherman; J Gopal; M Schlumberger; I D Hay
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

Review 6.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

7.  Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.

Authors:  F Pacini; L Agate; R Elisei; M Capezzone; C Ceccarelli; F Lippi; E Molinaro; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

Review 8.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Authors:  Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

9.  Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.

Authors:  A J Brendel; B Lambert; M Guyot; R Jeandot; H Dubourg; P Roger; S Wynchauk; G Manciet; G Lefort
Journal:  Eur J Nucl Med       Date:  1990

10.  Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.

Authors:  A M Samuel; B Rajashekharrao
Journal:  J Nucl Med       Date:  1994-12       Impact factor: 10.057

View more
  2 in total

1.  Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.

Authors:  Dong-Jun Lim; Joo Hyun O; Min-Hee Kim; Ji-Hyun Kim; Hyuk-Sang Kwon; Sung-Hoon Kim; Moo-Il Kang; Bong-Yun Cha; Kwang-Woo Lee; Ho-Young Son
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

2.  Nuclear Molecular and Theranostic Imaging for Differentiated Thyroid Cancer.

Authors:  Arif Sheikh; Berna Polack; Yvette Rodriguez; Russ Kuker
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.